Objective: To analyze and evaluate the therapeutic effect of Yiqi Huoxue Formula on patients with unstable angina pectoris of Qi deficiency and blood stasis syndrome. Methods: A total of 95 patients with unstable angina pectoris admitted to our hospital from January to December 2025 were selected for the study. They were randomly divided into a control group (47 cases) and an observation group (48 cases) using a random number table. The control group received conventional Western medicine intervention, while the observation group was additionally treated with Yiqi Huoxue Formula. The changes in traditional Chinese medicine (TCM) syndrome scores, clinical efficacy, angina symptom scores, inflammatory markers, cardiac troponin I (cTnI), and the discontinuation or reduction rate of nitroglycerin tablets were compared between the two groups. Results: Compared with the control group, the TCM syndrome scores in the observation group significantly decreased after treatment (p < 0.05). The total effective rates in the observation and control groups were 93.75% and 76.60%, respectively (p < 0.05). Compared with before treatment, the angina symptom scores in both groups decreased after treatment, with a greater reduction observed in the observation group (p < 0.05). Compared with the control group, the observation group had lower levels of IL-6, hs-CRP, and cTnI after treatment (p < 0.05). The total discontinuation or reduction rates of nitroglycerin in the observation and control groups were 79.17% and 53.19%, respectively (p < 0.05). Conclusion: For patients with unstable angina pectoris of Qi deficiency and blood stasis syndrome, the addition of Yiqi Huoxue Formula to Western medicine treatment can effectively alleviate their clinical symptoms and reduce TCM syndromes, reduce inflammatory responses and myocardial injury levels, enhance clinical efficacy, and help reduce nitroglycerin usage, demonstrating good clinical application value.